Eli Lilly to Invest $6 Billion in New API Manufacturing Facility in Alabama, USA
The new Huntsville, Alabama site will produce small molecule and peptide medicines, including oral GLP-1 orforglipron Eli Lilly and Company
Read more
Latest
Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision
Striatech is pleased to announce its next Journal Club: Gene-Agnostic Gene Therapy to Preserve Vision, which will be held on
Read more
Merck Announces $70 Billion U.S. Manufacturing and R&D Expansion
Merck & Co., Inc. announced on Monday a sweeping expansion of its U.S. operations, pledging more than $70 Billion in
Read more
Pfizer Strikes Landmark Deal with Trump Administration to Cut Drug Prices for U.S. Patients
Pfizer Inc. has reached a sweeping agreement with the Trump Administration that will reduce prescription drug costs for U.S. patients
Read more
AstraZeneca to Pursue Direct NYSE Listing
AstraZeneca, the Anglo-Swedish pharmaceutical giant, announced on Monday, plans to harmonise its share listing structure across the London Stock Exchange
Read more
Roche to Acquire 89bio in $3.5 Billion Deal Bolstering its MASH Pipeline
The definitive merger agreement, valued at up to $3.5 billion, grants Roche control of the late-stage FGF21 analog, pegozafermin, for
Read more
Merck’s KEYTRUDA QLEX™ Secures FDA Approval as First Subcutaneous Pembrolizumab Injection
Merck & Co., known as MSD outside of the United States and Canada, announced on Saturday that the U.S. Food
Read more
FDA Approves J&J’s Inlexzo™ Breakthrough Bladder Cancer Therapy
Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved INLEXZO™ (gemcitabine intravesical system), a
Read more
Boehringer’s HERNEXEOS® Wins Accelerated FDA Nod in Lung Cancer
In a landmark decision for HER2-mutant lung cancer, the US FDA has granted accelerated approval to Boehringer Ingelheim’s HERNEXEOS® (zongertinib),
Read more
Sanofi Secures China Rights to RNAi Candidate for Hypertriglyceridemia from Arrowhead
In a major regional licensing agreement, Sanofi has entered into an asset purchase deal with Visirna Therapeutics, a majority-owned subsidiary
Read more